KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Operations (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cash from Operations for 9 consecutive years, with 41302000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Operations rose 3119.15% year-over-year to 41302000.0, compared with a TTM value of 16817000.0 through Jun 2025, up 120.05%, and an annual FY2025 reading of 347369000.0, up 767.76% over the prior year.
  • Cash from Operations was 41302000.0 for Q2 2025 at Biocryst Pharmaceuticals, up from 27517000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 41302000.0 in Q2 2025 and bottomed at 53684000.0 in Q1 2024.
  • Average Cash from Operations over 3 years is 13337600.0, with a median of 13866000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations decreased 12.99% in 2024, then soared 3119.15% in 2025.
  • Year by year, Cash from Operations stood at 8918000.0 in 2023, then soared by 41.55% to 5213000.0 in 2024, then surged by 892.29% to 41302000.0 in 2025.
  • Business Quant data shows Cash from Operations for BCRX at 41302000.0 in Q2 2025, 27517000.0 in Q1 2025, and 5213000.0 in Q4 2024.